HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 8 (August)

1. HIV prevalence and predictors of infection in sex-trafficked Nepalese girls and women.
   JAMA, 298(5): 536-42. [Abstract] [Full-text]
2. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy.
   Obstet Gynecol, 110(2): 391-7. [Abstract] [Full-text]
3. Perioperative morbidity and mortality among human immunodeficiency virus infected women undergoing cesarean delivery.
   Obstet Gynecol, 110(2): 385-90. [Abstract] [Full-text]
4. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
   Pediatrics, 120(2): e416-23. [Abstract] [Full-text]
5. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample.
   Pediatrics, 120(2): e236-43. [Abstract] [Full-text]
6. HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversity.
   Nat Clin Pract Neurol, 3(8): 436-43. [Abstract] [Full-text]
7. Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART).
   Hepatology, 46(2): 359-70. [Abstract] [Full-text]
8. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES).
   J Behav Med, 30(5): 359-70. [Abstract] [Full-text]
9. Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum.
   J Behav Med, 30(5): 371-83. [Abstract] [Full-text]
10. Sexual abstinence only programmes to prevent HIV infection in high income countries: systematic review.
    BMJ, 335(7613): 248. [Abstract] [Full-text]
11. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons.
    J Infect Dis, 196(5): 684-91. [Abstract] [Full-text]
12. CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation.
    J Infect Dis, 196(5): 677-83. [Abstract] [Full-text]
13. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    J Infect Dis, 196(5): 670-6. [Abstract] [Full-text]
14. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
    Lancet, 370(9585): 407-13. [Abstract] [Full-text]
15. Beyond the end of exceptionalism: integrating HIV testing into routine medical care and HIV prevention.
    Expert Rev Anti Infect Ther, 5(4): 581-9. [Abstract] [Full-text]
16. Predictors of condom use and HIV testing among midlife and older women seeking medical services.
    J Aging Health, 19(4): 705-19. [Abstract] [Full-text]
17. Comorbid substance use and HIV risk in older African American drug users.
    J Aging Health, 19(4): 646-58. [Abstract] [Full-text]
18. Central activation, muscle performance, and physical function in men infected with human immunodeficiency virus.
    Muscle Nerve, 36(3): 374-83. [Abstract] [Full-text]
19. Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.
    Clin Infect Dis, 45(5): 658-61. [Abstract] [Full-text]
20. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.
    Clin Infect Dis, 45(5): 654-7. [Abstract] [Full-text]
21. Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?
    Clin Infect Dis, 45(5): 650-3. [Abstract] [Full-text]
22. Baseline HIV type 1 coreceptor tropism predicts disease progression.
    Clin Infect Dis, 45(5): 643-9. [Abstract] [Full-text]
23. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Clin Infect Dis, 45(5): 637-42. [Abstract] [Full-text]
24. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Clin Infect Dis, 45(5): 624-32. [Abstract] [Full-text]
25. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
    Clin Infect Dis, 45(5): 618-23. [Abstract] [Full-text]
26. A seronegative case of HIV-1 subtype C infection in Botswana.
    Clin Infect Dis, 45(5): e68-71. [Abstract] [Full-text]
27. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Clin Infect Dis, 45(5): e60-7. [Abstract] [Full-text]
28. Primary human immunodeficiency virus infection during pregnancy detected by repeat testing.
    Am J Obstet Gynecol, 197(2): 149.e1-5. [Abstract] [Full-text]
29. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus.
    Am J Obstet Gynecol, 197(2): 144.e1-8. [Abstract] [Full-text]
30. Molecular construction of bionanoparticles: chimaeric SIV p17-HIV I p6 nanoparticles with minimal viral protein content.
    Biotechnol Appl Biochem, 48: 35-43. [Abstract] [Full-text]
31. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians.
    J Gen Intern Med, 22(9): 1325-9. [Abstract] [Full-text]
32. The association between life chaos, health care use, and health status among HIV-infected persons.
    J Gen Intern Med, 22(9): 1286-91. [Abstract] [Full-text]
33. Darunavir (TMC114): a new HIV-1 protease inhibitor.
    Expert Opin Pharmacother, 8(12): 1951-64. [Abstract] [Full-text]
34. Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.
    Expert Opin Pharmacother, 8(12): 1871-84. [Abstract] [Full-text]
35. Single-molecule study of the inhibition of HIV-1 transactivation response region DNA/DNA annealing by argininamide.
    J Am Chem Soc, 129(33): 10181-8. [Abstract] [Full-text]
36. Protease inhibitors as immunomodulatory drugs for HIV infection.
    Clin Pharmacol Ther, 82(3): 248-50. [Abstract] [Full-text]
37. Virus-associated host CD62L increases attachment of human immunodeficiency virus type 1 to endothelial cells and enhances trans infection of CD4+ T lymphocytes.
    J Gen Virol, 88: 2568-73. [Abstract] [Full-text]
38. Increasing genetic diversity of hepatitis C virus in haemophiliacs with human immunodeficiency virus coinfection.
    J Gen Virol, 88: 2513-9. [Abstract] [Full-text]
39. Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association.
    J Virol, 81(17): 9193-201. [Abstract] [Full-text]
40. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
    J Virol, 81(17): 9408-18. [Abstract] [Full-text]
41. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
    J Virol, 81(17): 9061-71. [Abstract] [Full-text]
42. Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9.
    J Virol, 81(17): 9078-87. [Abstract] [Full-text]
43. Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells.
    J Virol, 81(17): 8933-43. [Abstract] [Full-text]
44. Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.
    J Virol, 81(17): 9268-78. [Abstract] [Full-text]
45. Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4+ T cells.
    J Virol, 81(17): 8878-90. [Abstract] [Full-text]
46. Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo.
    J Virol, 81(17): 9572-6. [Abstract] [Full-text]
47. The design of artificial retroviral restriction factors.
    Virology, 365(2): 302-14. [Abstract] [Full-text]
48. A whole-genome association study of major determinants for host control of HIV-1.
    Science, 317(5840): 944-7. [Abstract] [Full-text]
49. Porcine thymic grafts protect human thymocytes from HIV-1-induced destruction.
    J Infect Dis, 196(6): 900-10. [Abstract] [Full-text]
50. Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease.
    J Infect Dis, 196(6): 895-9. [Abstract] [Full-text]
51. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women.
    J Infect Dis, 196(6): 887-94. [Abstract] [Full-text]
52. Changes in prevalence of HIV infection and sexual risk behavior in men who have sex with men in San Francisco: 1997 2002.
    Am J Public Health, 97(9): 1677-83. [Abstract] [Full-text]
53. The use of herbal medicines in early drug development for the treatment of HIV infections and AIDS.
    Expert Opin Investig Drugs, 16(9): 1355-64. [Abstract] [Full-text]
54. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    J Med Virol, 79(10): 1464-71. [Abstract] [Full-text]
55. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men.
    J Med Virol, 79(10): 1446-54. [Abstract] [Full-text]
56. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
    J Med Virol, 79(10): 1562-8. [Abstract] [Full-text]
57. Diverse genotypes of Kaposi's sarcoma associated herpesvirus (KSHV) identified in infant blood infections in African childhood-KS and HIV/AIDS endemic region.
    J Med Virol, 79(10): 1555-61. [Abstract] [Full-text]
58. Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load <50 copies/ml.
    J Med Virol, 79(10): 1440-5. [Abstract] [Full-text]
59. High diversity of HHV-8 molecular subtypes in the Amazon region of Brazil: evidence of an ancient human infection.
    J Med Virol, 79(10): 1537-44. [Abstract] [Full-text]
60. Molecular epidemiology of HIV-1 in Santa Catarina State confirms increases of subtype C in Southern Brazil.
    J Med Virol, 79(10): 1455-63. [Abstract] [Full-text]
61. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
    J Med Virol, 79(10): 1593-9. [Abstract] [Full-text]
62. HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.
    J Mol Biol, 372(2): 369-81. [Abstract] [Full-text]
63. HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV-8+ lymphoproliferative disorders expands.
    Am J Surg Pathol, 31(9): 1439-45. [Abstract] [Full-text]
64. The incorporation of the HIV/AIDS identity into the self over time.
    Qual Health Res, 17(7): 919-31. [Abstract] [Full-text]
65. Hope is forked: hope, loss, treatments, and AIDS dementia.
    Qual Health Res, 17(7): 866-72. [Abstract] [Full-text]
66. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    PLoS Med, 4(8): e257. [Abstract] [Full-text]
67. Elevated serum levels of interferon- gamma -inducible protein-10 in patients coinfected with hepatitis C virus and HIV.
    J Infect Dis, 196(7): 1053-7. [Abstract] [Full-text]
68. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    J Infect Dis, 196(7): 1044-52. [Abstract] [Full-text]
69. Is it time to rethink the expanded-access programs for HIV infection?
    J Infect Dis, 196(7): 974-7. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.